You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lysine kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Lymphoma, Mantle-Cell
    • (no location specified)
    Dec 22, 2022

    Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Nov 28, 2022

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)

    Recruiting
    • Sjogren's Syndrome
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 24, 2022

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Breast Cancer Trial in Guangzhou (Take probiotics)

    Recruiting
    • Breast Cancer
    • Take probiotics
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 6, 2023

    Kinase Inhibitor Targeted Therapies

    Not yet recruiting
    • Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
    • Measurement of drug concentrations
    • Rennes, France
    • +2 more
    Nov 7, 2022

    Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

    Completed
    • Gastrointestinal Stromal Tumors (GISTs)
    • Imatinib Mesylate
    • Seoul, Korea, Republic of
      Asan Medical Center
    Dec 30, 2022

    Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma Trial in Saint Louis (device, drug, procedure)

    Recruiting
    • Pancreas Cancer
    • +2 more
    • MR-guided stereotactic body radiation therapy
    • +3 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 29, 2023

    SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

    Recruiting
    • SCLC
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

    Active, not recruiting
    • Neurofibromatosis 1
    • Neurofibroma Plexiform
    • Shanghai, China
    • +1 more
    Jan 13, 2023

    Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • East Melbourne, Victoria, Australia
    • +7 more
    Jan 20, 2023

    Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

    Active, not recruiting
    • Multiple Sclerosis
    • tolebrutinib 60mg
    • tolebrutinib 120mg
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Janus Kinase Inhibitor Therapy in Ulcerative Colitis

    Terminated
    • Ulcerative Colitis
    • Janus Kinase Inhibitor
    • Amsterdam, North Halland, Netherlands
      Amsterdam Medical Center, IBD Center
    Dec 14, 2021

    Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

    Not yet recruiting
    • Liver Transplant; Complications
    • +3 more
    • multi-kinase inhibitors in combination with bevacizumab
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences & Peking Union Medical Colle
    Sep 11, 2023

    High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

    Recruiting
    • High-Risk Localized Soft Tissue Sarcoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

    Recruiting
    • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 29, 2022

    Cancer Trial in Changsha (Protein Kinase Inhibitor)

    Recruiting
    • Cancer
    • Protein Kinase Inhibitor
    • Changsha, Hunan, China
      Central South University
    Jun 23, 2022